Fundraising FoxRallybio Holdings
NASDAQ: RLYBFarmington, US · Founded 2018 · Delaware corporation · 3 known investors
Find your way into Rallybio Holdings
Sign up to find every way you can get introduced to Rallybio Holdings
- Your email: who you already know at Rallybio Holdings, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Rallybio Holdings team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases, with a lead program in RLYB116, a C5 complement inhibitor in clinical development, and a preclinical program in RLYB332, a matriptase-2 antibody for iron overload disorders. The company has agreed to merge with Candid, a clinical-stage biotech focused on T-cell engager therapeutics for autoimmune diseases.
Founders & leadership
Rallybio Holdings was founded in 2018 by Jeffrey M. Fryer.
Investors · 3
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$157.8M disclosed across 3 rounds · 2018–2024
▶$6.6MraisedApr 2024 · 1 investors · PharmaceuticalsRule 506(b)
- MARTIN W. MACKAYDirector
- PAULA SOTEROPOULOSDirector
- KUSH M. PARMARDirector
- CHRISTINE A. NASHDirector
- HUI LIUDirector
- LUCIAN IANCOVICIDirector
- RONALD M. HUNTDirector
- ROB HOPFNERDirector
- WENDY K. CHUNGDirector
- HELEN M. BOUDREAUDirector
- STEPHEN UDENExecutive Officer, Director
- JONATHAN I. LIEBERExecutive Officer
- Offering amount
- $6.6M
- Amount sold
- $6.6M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$145.2MraisedMay 2020 · 28 investors · Other Health CareRule 506(b)
- Kush ParmarDirector
- Tim ShannonDirector
- Ketan PatelDirector
- Robert HopfnerDirector
- Martin MackayExecutive Officer, Director
- Lucian IancoviciDirector
- Jeffrey FryerExecutive Officer
- Stephen UdenExecutive Officer
- Ron HuntDirector
- Offering amount
- $145.2M
- Amount sold
- $145.2M
- First sale
- Mar 2020
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$6MraisedMay 2018 · 7 investors · Other Health CareRule 506(b)
- Martin W. MackayExecutive Officer, Director
- Stephen UdenExecutive Officer, Director
- Jeffrey M. FryerExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Apr 2018
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Rallybio Holdings do?
- Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases, with a lead program in RLYB116, a C5 complement inhibitor in clinical development, and a preclinical program in RLYB332, a matriptase-2 antibody for iron overload disorders. The company has agreed to merge with Candid, a clinical-stage biotech focused on T-cell engager therapeutics for autoimmune diseases.
- Who founded Rallybio Holdings?
- Rallybio Holdings was founded by Jeffrey M. Fryer in 2018.
- Who are Rallybio Holdings's investors?
- Rallybio Holdings's investors include 5AM Ventures, Canaan Partners, Pivotal Life Sciences.
- How much funding has Rallybio Holdings raised?
- Rallybio Holdings has disclosed $157.8M raised across 3 rounds.
- Where is Rallybio Holdings headquartered?
- Rallybio Holdings is headquartered in Farmington, US.